lasme-cel (UCART22)
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Phase 2Active (Pivotal BALLI-01 trial)
Key Facts
Indication
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Phase
Phase 2
Status
Active (Pivotal BALLI-01 trial)
Company
About Cellectis
Cellectis is a French-American biotech with 25 years of expertise in gene editing, focused on developing next-generation, 'off-the-shelf' CAR T-cell therapies to address significant unmet needs in oncology. The company's core platform combines its flagship TALEN® technology for ultra-precise genome editing with its PulseAgile electroporation system for efficient cellular engineering. With a robust pipeline of allogeneic CAR T candidates and strategic global partnerships with companies like Allogene, Servier, and AstraZeneca, Cellectis aims to transform cancer treatment by making cell therapies more accessible and scalable.
View full company profile